Advertisement

Topics

Efficacy and Safety of Frequently Modified Intensive Insulin

2014-08-27 03:17:56 | BioPortfolio

Summary

The purpose of this study is to evaluate the efficacy and safety of frequently modified intensive insulin therapy in patients with Type-2 and Type-1 diabetes mellitus.

Description

Insulin treatment is the mainstay of Type-1 diabetic management and one of the cornerstones in Type-2 diabetes. This treatment is based on multiple daily injections of different types of insulin. Patients follow their endocrinologists' directions by adhering to a set of recommended dosages and formulas, calculated by repeated blood glucose measurements. In order to maintain effective and safe management, glucose measurements are taken before meals and at bedtime, albeit imposing a heavy financial burden on a patient and their support system. For illustration, each disposable glucosemeter strip costs more than a dollar and needs to be replaced routinely 4 times daily, yielding an annual cost of more than $1500 per patient. Insulin dosages necessitate repeated adjustments to meet the patient's changing needs. Variations in food intake, body weight, physical activity, on going medical conditions and mood can impact a patient's insulin needs.

Accordingly, at each diabetic clinic appointment, the endocrinologist reviews the patient's glucose measurements and insulin doses to determine whether the insulin dosage needs to be adjusted. Unfortunately, limited appointment availability restricts insulin dosages adjustments to once every several months. Furthermore, as a result of the limited time allotted for each patient, new dosing recommendations are based on a review of only the most recent measurements. This drawback may be one of the chief causes of suboptimal management, with merely 38% of diabetic patients able to achieve proper control and mitigate detrimental complications.

Since the discovery of insulin by Frederick Grant Banting in 1921, only stringent glucose control by a regimen of multiple insulin injections has prevented microvascular and macrovascular complications in Type 1 diabetic patients. Moreover, insulin treatment amongst other treatment modalities has been shown to prevent microvascular and macrovascular complications in Type-2 diabetic patients. Incidentally, as the Type-2 diabetic epidemic expands, insulin treatment is becoming one of the main treatment modalities. Not taking into consideration availability, it has been established that more frequent patient-clinic interactions improve diabetic management in both Type-1 and Type-2 patients.

In a typical 3-6 month interval appointment, the endocrinologist would measure a patient's hemoglobin A1c (HbA1c) to determine the quality of the last 3 months control. This value, is linearly correlated to mean glucose levels at that 3 months period and, therefore, can be predicted according to the measurements. We used anonymous records of glucose measurements to perform preliminary statistical analysis. Our results indicate that a patient's glucose level is a highly non-stationary process, with strong variations in both mean and standard deviation (SD) from one week to another. In many patients with excessive HbA1c, which are at levels that diabetic complications are likely to ensue, the endocrinologist is obligated to adjust the insulin dosage based on a review of the patient's most recent glucose values and the values of the past several weeks. Furthermore, since appointment timing is random and independent from the patient's measurements, random trends in glucose values may be identified that lead to different conclusions. For illustration, if a patient's appointment happens to occur when his glucose values randomly trend up, the endocrinologist may choose to increase insulin doses. On the other hand, if the appointment occurs at a time when the glucose levels trend down, he may act oppositely. The required frequency of follow-up and dose adjustment that yields better patient control is yet to be determined.

Studies have shown that case management in patients with Type-2 diabetes can allow better control of HbA1c levels. These studies have involved using qualified medical professionals (ie, nurses, pharmacists, physician's assistants) as intervention methods, as well as providing counseling and follow-up calls to help patients with improved self-management of diabetes.

This study is designed to show that weekly insulin dosage adjustments for intensive insulin therapy are superior to conservative, infrequent adjustments during clinical appointments in both Type-1 and Type-2 diabetes.

Study Design

Control: Historical Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Diabetes

Intervention

Intensive insulin therapy

Location

TKL Research INC.
Paramus
New Jersey
United States
07652

Status

Completed

Source

Hygieia, Inc

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:17:56-0400

Clinical Trials [3369 Associated Clinical Trials listed on BioPortfolio]

Study of Intensive, Home-Based Family Therapy to Improve Illness Management in Youth With Diabetes

The study is a randomized clinical trial testing the effectiveness of Multisystemic Therapy (MST) for improving the treatment adherence, metabolic control and quality of life of urban adol...

Physiologic Insulin Therapy for the Management of Hyperglycemia in the Hospital

Many hospitals have begun giving insulin to nearly all patients with diabetes while they are in the hospital even if a patient does not use insulin at home. Controlling blood sugar with in...

Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy

This randomized controlled prospective study aims to evaluate the efficacy of intensive insulin therapy for long term glycemic control and improvement or preservation of beta cell function...

Flexible, Intensive Insulin Therapy in Patients With Type 1 Diabetes

To prospectively evaluate the long term metabolic and psychological effects of flexible intensive insulin therapy (FIT) courses in an unselected population of type 1 diabetic patients at t...

Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes

To determine in subjects with Type 1 Diabetes Mellitus: 1. Whether glycemic control can be achieved at least as effectively with a) an intensive insulin regimen involving pre-meal ...

PubMed Articles [14781 Associated PubMed Articles listed on BioPortfolio]

A 2-year Trial of Intermittent Insulin Therapy versus Metformin for the Preservation of Beta-cell Function after Initial Short-term Intensive Insulin Induction in early Type 2 Diabetes.

When administered in early type 2 diabetes (T2DM), short-term intensive insulin therapy (IIT) can improve reversible beta-cell dysfunction and induce subsequent remission of diabetes. However, this re...

Does insulin therapy matter? Determinants of diabetes care outcomes.

To evaluate adherence to care standards for people with diabetes (PWDs) on insulin therapy versus PWDs who are not on insulin therapy, controlling for social determinants.

Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes.

Insulin pump therapy may improve metabolic control in young patients with type 1 diabetes, but the association with short-term diabetes complications is unclear.

Switching to insulin glargine 300 U/mL: is duration of prior basal insulin therapy important?

To assess the impact of duration of prior basal insulin therapy on study outcomes in people with type 2 diabetes mellitus receiving insulin glargine 300 U/mL (Gla-300) or insulin glargine 100 U/mL (Gl...

Insulin regimens and glycemic control in different parts of Europe over 4years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study.

A number of insulin regimens are used in type 2 diabetes. This analysis aims to better understand the evolution of insulin therapy in different regions of Europe.

Medical and Biotech [MESH] Definitions

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).

Diabetes mellitus induced by PREGNANCY but resolved at the end of pregnancy. It does not include previously diagnosed diabetics who become pregnant (PREGNANCY IN DIABETICS). Gestational diabetes usually develops in late pregnancy when insulin antagonistic hormones peaks leading to INSULIN RESISTANCE; GLUCOSE INTOLERANCE; and HYPERGLYCEMIA.

A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.

A strain of Rattus norvegicus which is a model for spontaneous insulin-dependent diabetes mellitus (DIABETES MELLITUS, INSULIN-DEPENDENT).

More From BioPortfolio on "Efficacy and Safety of Frequently Modified Intensive Insulin"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...


Searches Linking to this Trial